Background: Noninvasive tools to measure myocardial stiffness are limited. Intrinsic cardiac elastography in echocardiography relates to myocardial stiffness by measuring the propagation of the myocardial stretch generated by atrial contraction. The aims of the present study were (1) to evaluate myocardial stiffness using intrinsic cardiac elastography in healthy volunteers versus those with myocardial diseases (ie, cardiac amyloidosis [CA] and hypertrophic cardiomyopathy) and (2) to identify key factors that affect myocardial stiffness.
Methods: In this prospective study, myocardial stiffness was estimated in 54 participants, including 10 hypertrophic cardiomyopathy, 28 CA, and 16 healthy volunteers. Myocardial stiffness was assessed as intrinsic velocity propagation of myocardial stretch (iVP, m/s) measured by high frame rate echocardiography (ie, above 250 frames per second). Extracellular volume was quantified by cardiac magnetic resonance in 22 participants. Amyloid burden was quantified by cardiac amyloid activity in Tc-labeled pyrophosphate single-photon emission computed tomography in 10 participants.
Results: Myocardial stiffness was significantly higher in the CA cohort (median iVP, 2.6 m/s; interquartile range, 1.7-3.9 m/s) than in the hypertrophic cardiomyopathy cohort (median iVP, 1.4 m/s; interquartile range, 1.0-1.8 m/s; =0.011). In patients with CA or hypertrophic cardiomyopathy, iVP was correlated with NT-proBNP (N-terminal pro-B-type natriuretic peptide) (ρ=0.498, =0.003), extracellular volume (ρ=0.646, =0.004), and cardiac amyloid activity (ρ=0.891, <0.001). In multivariate linear regression analysis, extracellular volume was independently associated with myocardial stiffness even after accounting for indexed left ventricular mass, global longitudinal strain, and E/e'. In healthy volunteers, normal myocardial stiffness was defined by the upper limit of normal of iVP at 1.7 m/s. Patients with CA and normal myocardial stiffness (iVP <1.7 m/s) were characterized by a low risk profile including lower NT-proBNP (=0.034), lower troponin T (=0.041), lower National Amyloidosis Center stage (=0.031), smaller interstitial expansion (=0.014), and smaller amyloid burden (=0.056).
Conclusions: Intrinsic cardiac elastography is a reliable noninvasive tool to measure myocardial stiffness. In this pilot study, it is related to imaging markers of interstitial expansion and amyloid burden.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/CIRCIMAGING.124.017475 | DOI Listing |
J Gen Physiol
May 2025
Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary.
Marfan syndrome (MFS) is an autosomal dominant disease caused by mutations in the gene (FBN1) of fibrillin-1, a major determinant of the extracellular matrix (ECM). Functional impairment in the cardiac left ventricle (LV) of these patients is usually a consequence of aortic valve disease. However, LV passive stiffness may also be affected by chronic changes in mechanical load and ECM dysfunction.
View Article and Find Full Text PDFMyocardial Infarction (MI) is a major contributor to morbidity and mortality, wherein blood flow is blocked to a portion of the left ventricle and leads to myocardial necrosis and scar formation. Cardiac remodeling in response to MI is a major determinant of patient prognosis, so many therapies are under development to improve infarct healing. Part of this development involves in vitro therapy screening which can be accelerated by engineered heart tissues (EHTs).
View Article and Find Full Text PDFUnlabelled: In addition to activation of muscle contraction by Ca , recent studies suggest that Ca also affects muscle passive mechanical properties. The goal of this study was to determine if Ca regulates the stiffness of cardiac muscle, independent of active contraction. The mechanical response to stretch for mouse demembranated cardiac trabeculae was probed at different Ca levels after eliminating active contraction using a combination of two myosin ATPase inhibitors: -nitroblebbistatin (PNB, 50 μM), plus mavacampten (Mava, 50 μM).
View Article and Find Full Text PDFCJC Open
February 2025
Department of Cardiology, Lady Davis Carmel Medical Centre, and the Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Background: Cardiac tamponade complicating transcatheter aortic valve replacement (TAVR) typically results from right ventricular (RV) injury induced by a pacemaker electrode, left ventricular (LV) injury induced by guidewires and catheters used during the procedure, and rupture of the aortic annulus during valve implantation.
Methods: We retrospectively analysed our institutional TAVR database to gain mechanistic insights relating to this complication.
Results: A total of 1247 TAVR procedures were performed from 2010 to 2024.
Cell Rep
March 2025
Aging and Cardiovascular Discovery Center, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA; Department of Cardiovascular Sciences, Lewis Katz School of Medicine, Temple University, Philadelphia, PA 19140, USA. Electronic address:
Cardiac amyloidosis is a secondary phenomenon of an already pre-existing chronic condition. Whether cardiac amyloidosis represents one of the complications post myocardial infarction (MI) has yet to be fully understood. Here, we show that amyloidosis occurs after MI and that amyloid fibers are composed of macrophage-derived serum amyloid A 3 (SAA3) monomers.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!